Millions of people take statins to lower LDL cholesterol and reduce their risk of heart attack and stroke, while cannabis use has become increasingly common among many of the same middle-aged and older adults. That overlap creates an important medication question: can someone taking atorvastatin, rosuvastatin, simvastatin, pravastatin, or another cholesterol drug safely use marijuana, THC, or CBD? The available evidence does not show that cannabis and statins are universally incompatible, but it does reveal several plausible and potentially important interactions—particularly with CBD and statins that depend heavily on liver enzymes for metabolism.
The most important limitation is that researchers have not yet conducted large controlled human trials specifically measuring statin concentrations before and after marijuana use. Much of the concern comes from what is known about statin pharmacology, laboratory studies of cannabinoids, controlled studies showing that CBD can inhibit human drug-metabolizing enzymes, and cardiovascular guidance from organizations such as the American Heart Association. This makes the interaction very different from a well-established contraindication. The evidence supports caution and medication review rather than automatically stopping either treatment. That distinction matters because the 2026 ACC/AHA guideline continues to identify statins as first-line therapy for reducing cardiovascular risk in appropriate patients.
How Statins Lower Cholesterol
Statins—including atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, and pitavastatin—reduce cholesterol production by inhibiting the liver enzyme HMG-CoA reductase. Lower cholesterol production encourages the liver to remove more LDL particles from circulation. Their importance extends beyond changing a laboratory number: statin treatment can substantially lower the risk of heart attack, ischemic stroke, and other complications of atherosclerotic cardiovascular disease. The updated 2026 ACC/AHA dyslipidemia guideline continues to place statins at the center of both primary and secondary cardiovascular prevention.
The statins do not all travel through the body in the same way, however. According to the 2026 ACC/AHA guideline, lovastatin and simvastatin rely heavily on CYP3A4 metabolism, while atorvastatin is also metabolized through CYP3A4 but to a lesser degree. Fluvastatin and several other statins involve CYP2C9 pathways, while pravastatin largely avoids cytochrome P450 metabolism. Rosuvastatin is also much less dependent on CYP metabolism than simvastatin or atorvastatin; FDA prescribing information states that only about 10 percent of a rosuvastatin dose is recovered as metabolites, with CYP2C9 responsible for the principal metabolite. Those differences help explain why medicinal cannabis use may pose more theoretical interaction risk with some statins than with others.
Why Marijuana and Statins May Interact
THC and CBD are both processed by liver enzyme systems that handle many prescription medications. Cannabidiol is particularly important because it can inhibit several cytochrome P450 enzymes. FDA clinical pharmacology material for prescription cannabidiol identifies inhibition of CYP2C9, CYP2C19, CYP3A4, and several other metabolic pathways in laboratory testing. The FDA also warns consumers more broadly that CBD can affect other medicines, potentially changing their effectiveness or increasing adverse effects.
The concern becomes clinically relevant when a statin depends on one of those same enzymes. If CBD reduces the activity of an enzyme responsible for clearing a statin, the statin could theoretically remain in the bloodstream at a higher concentration or for a longer period. Higher statin exposure does not necessarily cause symptoms, but increasing exposure can raise the risk of recognized statin adverse effects, particularly muscle pain, myopathy, and—in rare severe cases—rhabdomyolysis. The American Heart Association’s scientific statement on cannabis and cardiovascular health specifically identifies CYP3A4-mediated interactions as a potential issue for statins other than pravastatin and rosuvastatin and recommends monitoring for adverse effects when interacting medications are used.
Statin and Cannabis Interaction Guide
| Statin | Main Metabolism | Potential Cannabis Interaction | Relative Concern |
|---|---|---|---|
| Simvastatin (Zocor) | CYP3A4 | CBD may inhibit CYP3A4 and potentially increase simvastatin exposure, raising muscle-side-effect risk | Higher |
| Lovastatin (Mevacor) | CYP3A4 | CBD may slow metabolism and potentially increase drug concentrations | Higher |
| Atorvastatin (Lipitor) | CYP3A4 | CBD may inhibit metabolism and potentially increase atorvastatin exposure | Moderate–Higher |
| Rosuvastatin (Crestor) | Limited metabolism; some CYP2C9 | Less dependent on CYP3A4, although CBD may still affect CYP2C9 and drug transport pathways | Lower–Moderate |
| Fluvastatin (Lescol) | Mainly CYP2C9 | CBD can inhibit CYP2C9, creating a potential interaction | Moderate |
| Pitavastatin (Livalo) | Minimal CYP metabolism | Fewer CYP-based interaction concerns, though cannabinoid interaction data remain limited | Lower |
| Pravastatin (Pravachol) | Minimal CYP metabolism | Less likely to have a major CYP-mediated interaction with THC or CBD | Lower |
Atorvastatin, Simvastatin and Lovastatin May Deserve More Caution
Atorvastatin, sold under the brand name Lipitor and as generics, is among the most frequently prescribed cholesterol medicines. FDA prescribing information identifies atorvastatin as a CYP3A4 substrate and warns that medicines that strongly inhibit CYP3A4 can substantially increase atorvastatin exposure. When concentrations become too high, the risk of muscle toxicity increases. The FDA label specifically warns that drug interactions capable of increasing atorvastatin exposure can contribute to myopathy and rhabdomyolysis.
Simvastatin is even more dependent on CYP3A4. The FDA states that simvastatin is a CYP3A4 substrate and that strong CYP3A4 inhibitors can increase exposure enough to increase the risk of myopathy and rhabdomyolysis. Lovastatin behaves similarly. This does not mean CBD has been shown to raise simvastatin levels to the same degree as potent prescription CYP3A4 inhibitors such as clarithromycin or itraconazole. No comparable controlled statin-CBD trial has demonstrated that. Rather, the overlapping metabolic pathway makes the interaction biologically plausible and gives clinicians a reason to be particularly attentive when someone taking simvastatin, lovastatin, or atorvastatin begins using significant amounts of CBD.
What About Rosuvastatin and Pravastatin?
Rosuvastatin and pravastatin are sometimes considered when drug interactions make CYP3A4-metabolized statins difficult to use. Pravastatin does not undergo clinically significant CYP3A4 metabolism, while rosuvastatin is only minimally metabolized overall. From a CYP3A4 perspective, that makes them less vulnerable than simvastatin and lovastatin. The American Heart Association has similarly distinguished pravastatin and rosuvastatin from statins that depend more heavily on CYP3A4.
That does not make them interaction-proof. Rosuvastatin’s limited metabolism involves CYP2C9, and cannabinoids—especially CBD—have demonstrated inhibition of CYP2C9 in experimental and human studies. Statin exposure can also be influenced by drug transport proteins rather than CYP metabolism alone. The practical conclusion is therefore not that a cannabis user should independently switch to rosuvastatin or pravastatin. Instead, a clinician or pharmacist may consider the patient’s statin, dose, other medications, liver and kidney function, and cannabis pattern when deciding whether the current cholesterol treatment remains appropriate.
CBD May Matter More Than THC for Metabolic Interactions
One of the strongest human studies of cannabinoid drug interactions came from researchers at Washington State University. Eighteen healthy adults consumed either a CBD-dominant cannabis brownie containing 640 mg CBD and 20 mg THC, a THC-dominant brownie containing 20 mg THC without CBD, or placebo. Researchers then administered drugs used as probes for major liver enzymes. The CBD-containing product increased exposure to the CYP3A probe midazolam by about 56 percent and the CYP2C9 probe losartan by about 77 percent, while producing even greater inhibition of CYP2C19.
The THC-only edible, by contrast, did not significantly inhibit any of the CYP pathways measured in that study. That is an important finding because people often talk about “cannabis interactions” as though THC and CBD have identical pharmacology. They do not. The CBD dose used in this experiment—640 mg—was far higher than the amount found in many ordinary consumer products, so the results should not be interpreted as proof that a 10- or 25-mg CBD gummy substantially increases atorvastatin levels. The experiment does, however, provide direct human evidence that sufficiently high oral CBD exposure can inhibit CYP3A and CYP2C9, the same families involved in several statins.
Could Cannabis Increase Statin Muscle Side Effects?
Muscle problems are the interaction that generally receives the most attention. Statin-associated symptoms can range from mild aching or weakness to myopathy accompanied by elevated creatine kinase. Rhabdomyolysis is much rarer but considerably more serious because rapid muscle breakdown can release myoglobin into the bloodstream and damage the kidneys. FDA labeling for atorvastatin specifically warns patients to report unexplained muscle pain, tenderness, or weakness, particularly when accompanied by fever or general illness.
Increasing statin concentration is one recognized way drug interactions can increase muscle toxicity. That is why potent CYP3A4 inhibitors are tightly restricted or contraindicated with certain statins. The theory behind a CBD-statin interaction follows the same pharmacological principle, but the strength of evidence is much weaker: there is not currently strong clinical evidence showing that marijuana or ordinary CBD products cause statin-induced rhabdomyolysis. Reviews of cardiovascular cannabis interactions describe increased atorvastatin, lovastatin, or simvastatin concentrations as anticipated based largely on metabolic pathways while acknowledging that direct clinical evidence remains limited.
Cannabis, Statins and the Liver
Both statins and CBD bring the liver into the discussion, although serious liver injury from statins is uncommon. The FDA cholesterol medication guide identifies liver problems as a potential statin adverse effect and advises clinicians to consider liver health when prescribing these medicines. CBD has a more clearly demonstrated dose-related potential to increase liver enzymes. During development of the prescription CBD drug Epidiolex, the FDA identified transaminase elevations and liver injury as important safety concerns, particularly at high pharmaceutical CBD doses and in combination with other medicines affecting the liver.
This does not mean a person taking a statin will damage their liver by using a low-dose CBD product. Much of the strongest CBD liver-safety evidence comes from prescription doses that may be hundreds of milligrams per day or calculated according to body weight—far beyond many retail CBD servings. Still, anyone taking a statin who regularly consumes high-dose CBD, has pre-existing liver disease, drinks substantial amounts of alcohol, or takes additional medications capable of affecting the liver has more reason to discuss monitoring with a healthcare professional.
Marijuana Has Cardiovascular Effects Beyond the Statin Interaction
There is another reason the question matters. Many statin users take cholesterol medication because they already have coronary artery disease or are at elevated risk for heart attack and stroke. Cannabis can influence the cardiovascular system independently of any effect on statin metabolism. The American Heart Association notes that THC can stimulate the sympathetic nervous system, alter heart rate and blood pressure, and increase myocardial oxygen demand. Its scientific statement concluded that many of cannabis’s potential health concerns involve cardiovascular effects and that patients with cardiovascular disease deserve particular consideration.
That means focusing exclusively on whether marijuana changes atorvastatin concentration can miss the larger clinical picture. A patient taking a high-intensity statin after a heart attack, for example, may also take aspirin, clopidogrel, a beta blocker, an anticoagulant, an ACE inhibitor, or a calcium-channel blocker. Cannabis and CBD can potentially interact with several of those medications through different mechanisms. For someone with established cardiovascular disease, a complete medication review is therefore more useful than checking the statin in isolation.
Does Smoking vs Taking Edibles Change the Interaction?
Route of administration can affect both cannabinoid exposure and interaction risk. Inhaled THC produces a rapid rise in blood concentration followed by a relatively rapid decline, while oral THC is absorbed more slowly and converted to active 11-hydroxy-THC in the liver. Oral CBD also undergoes substantial first-pass metabolism and may remain at pharmacologically relevant concentrations for many hours. Because the strongest demonstrated CYP inhibition has generally involved substantial systemic CBD exposure, high-dose oral CBD products may deserve more interaction attention than occasional low-dose THC exposure.
Smoking introduces a different metabolic phenomenon because combustion products can induce CYP1A2. That pathway is important for several psychiatric and other medications but is not the dominant route for the major statins discussed here. For cholesterol medication, the better-established theoretical concern remains inhibition of CYP3A4 or CYP2C9 by cannabinoids—especially CBD—rather than smoke-induced CYP1A2 changes. Product composition also matters because a product labeled simply “cannabis” can range from high-THC flower to a CBD-rich tincture containing hundreds of milligrams of cannabidiol.
Can You Use Marijuana While Taking a Statin?
For many people, taking a statin does not automatically mean cannabis must be avoided completely. Current evidence does not establish a universal prohibition against using marijuana with atorvastatin, rosuvastatin, pravastatin, or other statins. The interaction concern is strongest when substantial CBD exposure overlaps with a statin highly dependent on CYP metabolism, when the statin dose is high, or when the patient already has other risk factors for muscle or liver toxicity.
The safer approach is to tell the prescribing clinician or pharmacist what cannabis products are actually being used. “I use marijuana” provides less useful information than explaining that someone takes a 100-mg CBD tincture every night, smokes high-THC flower twice weekly, or consumes a balanced THC/CBD edible daily. Starting or stopping a high-dose CBD product can be especially relevant because changing cannabinoid exposure may change enzyme inhibition. Statins should generally not be stopped or reduced without medical guidance, particularly in people taking them because of known cardiovascular disease or previous heart attack or stroke. The cardiovascular benefit of appropriate statin therapy is well established, while the magnitude of most cannabis-statin interactions remains uncertain.
Symptoms That Should Not Be Ignored
Someone taking both cannabis products and a statin should pay particular attention to new, unexplained muscle symptoms. Persistent muscle pain, unusual tenderness, pronounced weakness, severe fatigue, or difficulty performing activities that were previously easy deserve medical evaluation, especially if symptoms begin after increasing a statin dose or starting regular CBD. Dark or cola-colored urine, severe muscle weakness, or major muscle pain can be warning signs of rhabdomyolysis and warrant prompt medical attention. FDA statin guidance identifies muscle problems severe enough to cause kidney injury as an important, although uncommon, statin risk.
Possible liver symptoms—including yellowing of the skin or eyes, dark urine, significant abdominal discomfort, unusual nausea, or marked fatigue—also deserve evaluation. Most people taking statins will never develop serious liver or muscle toxicity, and experiencing ordinary aches does not automatically mean cannabis caused a drug interaction. The point of monitoring is to recognize unusual changes early rather than assuming every symptom is harmless.
Final Thoughts on Cannabis and Statins
The relationship between cannabis and cholesterol medication is best described as plausible, statin-specific, and still incompletely studied. CBD can inhibit CYP3A4 and CYP2C9 in humans, and those enzymes participate in the metabolism of several commonly prescribed statins. Simvastatin and lovastatin are particularly dependent on CYP3A4, while atorvastatin also uses that pathway. Rosuvastatin is much less extensively metabolized and pravastatin largely avoids CYP metabolism, giving different statins different theoretical interaction profiles.
What researchers have not yet demonstrated is equally important. There is no strong body of controlled clinical evidence showing that ordinary marijuana use consistently raises statin blood concentrations, causes statin myopathy, or requires routine statin dose changes. High-dose CBD deserves the greatest attention because direct human research has demonstrated meaningful inhibition of CYP enzymes, whereas a controlled THC-only exposure did not produce the same inhibition. The FDA nevertheless advises consumers that CBD can interact with medications, and the American Heart Association recognizes potential interactions between cannabinoids and cardiovascular drugs, including statins.
For someone who relies on a statin to reduce cardiovascular risk, the best response is therefore not to abandon cholesterol medication because cannabis is being used. Instead, the exact statin, dose, THC and CBD exposure, other medications, liver and kidney health, and history of muscle side effects should be considered together. As cannabis pharmacology becomes better studied, specific recommendations may become clearer. For now, occasional THC use and high-dose daily CBD should not be treated as equivalent exposures, and patients using both cannabinoids and statins benefit from making cannabis part of the same medication conversation as every other prescription, supplement, and over-the-counter drug.
